NorthX Biologics Secures Significant Investment from Signet Healthcare Partners
Deal News | May 14, 2025 | Signet Healthcare Partners LLC
Signet Healthcare Partners, a prominent US-based private equity firm with a substantial history in pharmaceutical services, has announced a significant investment in NorthX Biologics, a leading Nordic biopharmaceutical CDMO. The investment aims to propel NorthX's ambitious expansion plans, enhancing facilities, broadening service offerings, and extending its US commercial reach. Known for delivering complex biologics manufacturing services, NorthX caters globally from its Swedish base. The transaction was executed through a new share issue, and post-investment, Signet’s James Gale will join NorthX’s Board of Directors. Flerie remains the major stakeholder. While specifics of the deal remain undisclosed, legal advisors included Setterwalls for NorthX and Advokatfirman Delphi, alongside Sheppard, Mullin, Richter & Hampton for Signet.
Sectors
- Biopharmaceutical
- Private Equity
Geography
- Sweden – NorthX Biologics is headquartered in Sweden and serves as a central hub for its global operations in advanced biologics.
- United States – Signet Healthcare Partners, the investing private equity firm, is based in the United States and aims to enhance NorthX Biologics' presence in the US market.
Industry
- Biopharmaceutical – NorthX Biologics operates within the biopharmaceutical sector, providing complex biologics manufacturing services globally. This sector is pivotal to their operations and expansion plans.
- Private Equity – Signet Healthcare Partners is a private equity firm focused on growth capital in healthcare, emphasizing their role in the financial backing and strategic guidance for biopharmaceutical firms like NorthX Biologics.
Financials
- Not Disclosed – The terms and amount of the investment made by Signet Healthcare Partners in NorthX Biologics were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NorthX Biologics AB | Target Company | Company | A leading Nordic biopharmaceutical CDMO providing a wide range of biologics manufacturing services and striving to expand globally. |
| Signet Healthcare Partners LLC | Investor | Company | A US-based private equity firm specializing in healthcare investments, providing growth capital and expertise to its portfolio companies. |
| Flerie AB | Major Shareholder | Company | An active investor in life sciences with a diversified portfolio focusing on innovative science and product development. |
| Setterwalls | Legal Advisor to NorthX Biologics | Company | Provided legal advisory services to NorthX Biologics during the investment transaction. |
| Advokatfirman Delphi | Legal Advisor to Signet | Company | Advised Signet Healthcare Partners legally on the investment transaction. |
| Sheppard, Mullin, Richter & Hampton | Legal Advisor to Signet | Company | Served as a legal advisor to Signet Healthcare Partners during the investment process. |
| James Gale | Board Member | Person | Managing Director at Signet Healthcare Partners, joining NorthX Biologics' Board of Directors post-transaction. |
| Janet Hoogstraate | Chief Executive Officer | Person | CEO of NorthX Biologics, overseeing the company's strategic direction and growth. |
| Thomas Eldered | Chairman | Person | Chairman of NorthX Biologics and Flerie, involved in strategic planning and overseeing the company's expansion. |